Vaxart Appoints New Board Member to Enhance Vaccine Development Expertise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: Newsfilter
- New Board Member: Vaxart has appointed Dr. James Breitmeyer to its Board, bringing over 35 years of biopharmaceutical experience, including leading eight FDA product approvals, which enhances the company's expertise in vaccine development.
- Clinical Development Leadership: As the former CEO of Oncternal Therapeutics, Dr. Breitmeyer oversaw the clinical development of first-in-class oncology assets, providing crucial support for Vaxart's clinical programs and advancing its oral vaccine platform.
- Vaccine Development Expertise: His previous role as President of Bavarian Nordic involved overseeing the development of cancer and infectious disease vaccines, equipping Vaxart to navigate complex regulatory environments more effectively.
- Strategic Collaboration Outlook: Vaxart anticipates that Dr. Breitmeyer's addition will further strengthen its competitive position in the global vaccine market, particularly in the innovation and promotion of oral vaccines, aiding the company in achieving broader vaccination goals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
